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Snumary A small (-30) but varied group of organic and inorganic compounds appear to be carcinogenic in
both humans and experimental animals. A much larger number and wider variety of chemical carcinogens,
primarily synthetic organic compounds, are known for experimental animals. These agents include a small
( 30) and varied group of metabolites of green plants and fungi. Many more of these carcinogens must exist
in the living world. As with the synthetic carcinogens, the majority of these naturally occurring carcinogens
are procarcinogens that require metabolic conversion into reactive electrophilic and mutagenic ultimate
carcinogens. These strong electrophiles combine covalently and non-enzymatically with nucleophilic sites in
DNAs, RNAs, proteins, and small molecules in target tissues. One or more of the DNA adducts appear to
initiate carcinogenesis in an irreversible manner. The subsequent promotion step leading to gross tumours
may be completed by further administration of carcinogen or by treatment with non-carcinogenic promoters.
Roles for the RNA and protein adducts in the carcinogenic process have not been excluded. Recent data on
the metabolic activation and reactivity in vivo of the naturally occurring carcinogens ethyl carbamate and
certain of the alkenylbenzene spice flavours are illustrative of these principles. These agents can initiate the
carcinogenic process in male mouse liver with small doses given prior to weaning. Subsequent growth of the
liver and male hormonal factors appear to function as promoters leading to gross hepatic tumors after one
year. Reactive electrophilic metabolites of ethyl carbamate and of safrole and estragole and their nucleic acid
adducts formed during initiation in mouse liver have been characterized.
The Walter Hubert Lecture has been given twice
before by members of the McArdle Laboratory,
namely by Dr. Charles Heidelberger and by Dr.
Van R. Potter. Indeed, Charles Heidelberger was
the first Walter Hubert Lecturer and spoke at the
BACR meeting held in Manchester in 1969. Sadly,
as many in this audience know, Charles Heidelberger
died of metastatic cancer in January of this year in
LosAngeles. He had been Director ofBasic Research
at the Cancer Center of the University of Southern
California since leaving McArdle in 1976. His
untimely death at age 62 is a great loss to cancer
research in the fields of chemical carcinogenesis and
experimental cancer chemotherapy, the two
principal fields in which he worked and excelled. As
long-time colleagues of his at the McArdle
Laboratory, we wish to dedicate this Walter Hubert
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Lecture to the memory of Charles Heidelberger and
his outstanding research on cancer.
As is evident from the overall topic of this
symposium and the papers that preceded this one
(see Abstracts of Proceedings-this issue), the
occurrence of chemical carcinogens in the human
environment has become a subject of wide public
concern. Much attention has been focussed on man-
made compounds since the early industrial studies
in Germany and in England and it is not fully
recognized that a wide variety of chemical
compounds with carcinogenic activity occur
naturally in the environment. These non-viral and
non-radioactive carcinogens occur in at least four
classes, as noted in Table I, which range from
minerals deposited in the earth's crust to
combustion products to products of living cells. As
naturally occurring carcinogens, these agents occur
in nature independently of human activities, but
many human activities can greatly increase the
exposure of small to large human populations to
each of these classes ofcarcinogenic agents.
The naturally occurring carcinogens of particular
interest for this presentation are those that are
made by living cells (Class 1). Most of these agents
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Table I Naturally occurring chemical carcinogens
1. Metabolites of living systems (especially from fungi
and green plants)
2. Pyrolysis products of organic matter (Polycyclic
aromatic hydrocarbons and related heteroaromatics;
polycyclic aromatic and heteroaromatic amines)
3. N-Nitroso compounds derived from nitrite and
biogenic aliphatic amines and amides
4. Inorganic compounds of beryllium, cadmium,
chromium, cobalt, lead, nickel, and platinum. Asbestos
(complex silicates)
are metabolites of fungi and green plants, as
exemplified in Figure 1. The pyrrolizidine alkaloids
were among the first of this group to receive serious
consideration as possible carcinogens and as agents
for which exposures might have important
consequences to man. Dr. Regina Schoental
pioneered in work on these compounds over 30
years ago. In addition to the carcinogenic
metabolites of plants, fungi and bacteria, a few
products found in animal cells (e.g., certain
metabolites of tryptophan) also are carcinogenic.
Some of these carcinogenic products of living cells
occur in certain common human foods, but most of
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them have been found either in unusual or minor
food sources or in contaminated foods. Although
only 30 of these carcinogenic metabolites of
living systems are now recognized (Miller & Miller,
1979), it appears virtually certain that many other
agents of this type exist. This statement is based in
part on our comparatively limited knowledge of the
components of natural products and of their toxic
properties. Thus, the great majority of the non-
nutritive, lipid-soluble, minor organic components
of foods have not yet been isolated, characterized,
and tested for biological activity.
The majority of chemical carcinogens, both
synthetic and naturally occurring compounds, do
not react chemically with cellular components such
as nucleic acids and proteins but they do form
covalently bound adducts with these
macromolecules in vivo (Miller & Miller, 1981).
Thus most chemical carcinogens require metabolic
activation in vivo to form electrophilic derivatives
(ultimate carcinogens) that react covalently with
nucleophilic N, 0, and S atoms in the purine,
pyrimidine and amino acid residues in nucleic acids
and proteins (Figure 2). One or more of the DNA
adducts of these carcinogens appears to be critical
in the initiation stage of carcinogenesis by these
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Figure 1 Some representative naturally occurring carcinogenic metabolites of fungi and green plants (Miller
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Figure 2 A current view of the mechanisms of action ofchemical carcinogens.
agents. The promotion phase of carcinogenesis may
also be facilitated by reactions of the electrophilic
metabolites, but data on this point are limited.
Roles for the RNA and protein-adducts in the
carcinogenic process have not been excluded.
Relatively little study has been made of the
metabolic activation and the DNA adducts of
fungal and plant carcinogens. The mycotoxins
and hepatocarcinogens aflatoxin B1 and
sterigmatocystin are metabolized to highly reactive
epoxides that form adducts primarily by reaction at
the N-7 position of guanine residues in liver DNA
(Wogan et al., 1979). Likewise, the streptomyces
metabolite and pancreatic carcinogen L-azaserine is
metabolized to release diazoacetic acid residues that
form N-7 carboxymethyl adducts of guanine bases
in DNA (Zurlo et al., 1982). The plant
hepatocarcinogen cycasin is metabolized to a
reactive species that methylates tissue DNA (Magee
et al., 1976). To extend this information we have
recently studied other naturally occurring
carcinogens from living systems. One is the
fermentation product ethyl carbamate that induces
tumours at several tissue sites in rodents. The
others are the hepatocarcinogens safrole and
estragole. These two carcinogens are plant products
and belong to the group of alkenylbenzene spice
flavouring agents.
Ethyl carbamate (urethan)
This simple structure (Figure 1) was discovered as a
synthetic carcinogen 40 years ago in the induction
of lung adenomas in mice which received it as an
anaesthetic (Mirvish, 1968). Previously, ethyl
carbamate had been used in some cases as a
sedative in humans. Recently, ethyl carbamate was
found to occur in fermented foods such as bread,
yogurt, beer, and wine at levels of 1-6pgkg-'
(Ough, 1976). It is formed in ethanolic
fermentations by the ethanolysis of carbamyl
phosphate. The risks to humans of daily intakes of
a few micrograms of ethyl carbamate from food
sources for several decades are not known but
appear to be very low. Much greater exposures of
humans to ethyl carbamate occurred in Japan from
approximately 1950-1975 from the use of this
amide as a co-solvent for barbiturate drugs
(Nomura, 1975). It is not clear whether or not it is
possible to analyze the long term consequences by
an epidemiological survey.
I4 J.A. MILLER & E.C. MILLER
Ethyl carbamate is a versatile carcinogen
(Mirvish, 1968) and can induce lung adenomas,
hepatomas, mammary carcinomas, thymic
lymphomas, and haemangiomas in mice. It also acts
as a pure initiator of tumour formation in mouse
skin and as a carcinogen in several tissues in rats
and hamsters (Mirvish, 1968).
Small structural changes in ethyl carbamate
generally produce large decreases in carcinogenicity
(Mirvish, 1968; Shimkin et al., 1969). For example,
methyl carbamate is inactive and n-propyl and
i-propyl carbamates have only weak activity in the
mouse. Only the ethyl carbons of ethyl carbamate
become bound covalently to the DNA in the mouse
liver in vivo and methyl, n-propyl and n-butyl
carbamate do not bind to liver DNA in significant
amounts (Lawson & Pound, 1973). These data
suggested that the ethyl group of ethyl carbamate
was involved in the activation of this carcinogen in
vivo.
A clue to an activation pathway for ethyl
carbamate in vivo developed from the finding of the
high carcinogenicity of vinyl carbamate
(CH2=CH-O-CO-NH2) (Dahl et al., 1978).
Tests on this carbamate were prompted by the
carcinogenicity of vinyl chloride in the liver and
other tissues of rats and mice (IARC, 1974). Vinyl
carbamate proved to be several- to many-fold more
active than ethyl carbamate in a number of tissues
in the mouse and rat (Dahl et al., 1978, 1980); it is
the first derivative of ethyl carbamate to exhibit
carcinogenic activities greater than those of the
parent compound. Vinyl carbamate was also
mutagenic for Salmonella typhimurium TA 1535 and
TA 100 in the presence of NADPH and mouse or
rat liver mitochondrial supernatant fractions (Dahl
et al., 1978). This mutagenic activity was inhibited
strongly by cytochome P-450 inhibitors. No
mutagenic activity was observed for vinyl
carbamate in the absence of added liver
preparations or for ethyl carbamate in the presence
or absence of liver fractions. The high
carcinogenicity of vinyl carbamate and its
mutagenicity with metabolic activation were
consistent with our hypothesis that it might be a
metabolite of ethyl carbamate and that its epoxide
might be an electrophilic metabolite capable of
reacting with tissue nucleophiles such as DNA.
However, extensive tests by isotope dilution (Dahl
et al., 1978, 1980) failed to detect any conversion of
ethyl carbamate to vinyl carbamate in mouse or rat
liver either in vivo or in vitro. Thus, an alternative
possibility is that both ethyl and vinyl carbamate
are converted in vivo to a common reactive
intermediate that effects the binding of the carbon
atoms from the ethyl and vinyl groups to cellular
DNA. No intermediate has been detected in our
tests to date.
In view of the above results an indirect approach,
based on the formation of etheno bases in hepatic
RNA of vinyl chloride-treated rats (Laib & Bolt,
1977, 1978), was used to probe the metabolism of
ethyl and vinyl carbamate in vivo. For this study
hepatic RNA from mice which had received
injections of [ethyl-1,2-3H]- or [ethyl-1-'4C]ethyl
carbamate was enzymatically hydrolyzed to the
nucleoside level. The presence of 1,N6-
ethenoadenosine and 3,N4-ethenocytidine in these
hydrolysates was demonstrated by comigration on
high performance liquid chromatography of 3H or
'4C from the ethyl carbamate with synthetic
standards (Ribovich et al., 1982). Both the hepatic
ethenoadenosine and ethenocytidine were further
characterized by their conversion to acetylated
products that also comigrated with the acetylated
synthetic standards. Similarly, the hepatic
ethenoadenosine was solvolyzed by anhydrous
trifluoroacetic acid to a product that comigrated
with 1,N6-ethenoadenine. Figures 3 and 4 show the
data obtained for ethenoadenosine with the tritiated
ethyl carbamate. Similar data were obtained for
3,N4-ethenocytidine with the tritiated carcinogen
and for both etheno nucleosides derived from the
'4C-labelled ethyl carbamate. No labelled
ethenoadenosine or ethenocytidine was detected in
liver RNA from mice treated with [1-'4C]ethanol,
which is a metabolite of ethyl carbamate in vivo
(Mirvish, 1968). Thus, ethyl carbamate, rather than
its hydrolysis product, is required for the formation
of the etheno bases in mouse liver RNA in vivo.
Approximately 7-1Opmol of ethenoadenosine and
2-3pmol of ethenocytidine were found per mg of
mouse liver RNA 6-12h following the
administration of 0.5mg of ethyl carbamate per g
body wt (Table II). This corresponds to -2 and 0.7
ethenoadenosine and ethenocytidine residues,
respectively, per 106 bases in RNA. Dr. Li in our
laboratory has developed a method which depends
on the very intense fluorescence of 1,N6-
ethenoadenosine in ultraviolet light (Barrio et al.,
1972) and permits comparisons of the formation of
Table II Hepatic RNA adducts formed from ethyl and
vinyl carbamate in B6C3F1 12-day male mice'
pmolmg1 RNA
Car- Dose Etheno- Etheno-
bamate Analytical method (pgg'1) adenosine cytidine
Ethyl [Ethyl-1,2-3H or 500 6-10 2-3
ethyl-1-"4C]ethyl
carbamate
Fluorometric 500 5-8
Vinyl Fluorometric 25 25-30
Fluorometric 50 45-50
aMice killed 6-12h after i.p. injection.THE 1983 WALTER HUBERT LECTURE 5
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Figure 3 High performance liquid chromatographic separation of tritiated ethenoadenosine from an
enzymatic hydrolysate of hepatic RNA from adult male mice given [ethyl-1,2-3H]ethyl carbamate (Ribovich et
al., 1982). The insert shows the pattern for a similar hydrolysate without addition ofmarker ethenoadenosine.
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Figure 4 Further characterization of the tritiated product from hepatic RNA that comigrated with l,N6-
ethenoadenosine in Figure 3. Panel A: Comigration on a cation exchange column; Panel B: Comigration on
the same column after the tritiated product was partially solvolyzed with trifluoroacetic acid; Panel C:
Comigration on a reverse-phase column of the tritiated product and synthetic ethenoadenosine after
acetylation with acetic anhydride.
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ethenoadenosine from unlabelled ethyl and vinyl
carbamates. By employing a highly sensitive
fluorescence detector and two successive
chromatographies to isolate pure ethenoadenosine,
as little as 1 pmol of ethenoadenosine can be
detected per mg RNA. With this fluorometric
method the yields of ethenoadenosine in hepatic
rRNA from mice treated with ethyl carbamate are
in good accord with those obtained with the labeled
ethyl carbamate (Table II). Furthermore,
administration of 25 or 50pg vinyl carbamate per g
body wt yielded several times more
ethenoadenosine in the RNA than did much larger
doses of ethyl carbamate (Table II). This latter
result is consistent with the much greater
carcinogenicity of vinyl carbamate as compared to
that of ethyl carbamate and with the formation of
vinyl carbamate or a derivative thereof as an
important intermediate in the metabolism of ethyl
carbamate to a reactive metabolite that is a
precursor of the etheno adducts.
Some further data obtained with the fluorometric
method for ethenoadenosine are of interest. Methyl
carbamate, which is not carcinogenic and does not
bind to mouse liver DNA in vivo, did not yield
detectable amounts of ethenoadenosine in hepatic
RNA. Presumably, at least a two carbon fragment
is required for the formation of the etheno bases in
vivo. The specificity for an ethyl group in these
reactions in vivo may be quite high. It is of further
interest to note the ethenoadenosine levels in non-
hepatic tissues in mice administered vinyl
carbamate. Vinyl carbamate is carcinogenic in the
lungs and thymus of the mouse, and it gave rise to
levels of ethenoadenosine in the RNA of these
tissues that were similar to those produced by this
carbamate in the liver. Under the same conditions
rRNA from the kidney, a non-target tissue, had
about one-fourth the amount of ethenoadenosine
found in hepatic rRNA.
Although less information is available on the
DNA adduct(s) formed in vivo from ethyl and vinyl
carbamate, it is evident that the pattern follows
that found for vinyl chloride (Laib & Bolt, 1977,
1978; Osterman-Golkar et al., 1977; Laib et al.,
1981). Thus, following administration of ethyl or
vinyl carbamate 7-(2-oxoethyl)guanine adducts,
rather than the etheno bases, are formed in liver
DNA. In preliminary communications Scherer et al.
(1980) and Scherer and Emmelot (1982) reported
that enzymatic hydrolysates of hepatic DNA from
rats and mice given [ethyl-l-"4C]ethyl carbamate
contained most of the "4C in one chromatographic
peak. Neutral heating or acid hydrolysis yielded a
product that comigrated with 7-(2-oxoethyl)guanine,
which was further characterized by its reduction to
a derivative that comigrated with 7-(2-
hydroxyethyl)guanine. The ease of reduction of 7-(2-
oxoethylguanine) provided a basis for a sensitive
method of quantitation-i.e., by incorporation of
tritium on reduction with tritiated sodium
borohydride. This procedure also permits the use of
unlabelled carbamates for in vivo studies. In recent
similar studies by Dr. Li in our laboratory vinyl
carbamate produced at least 20-fold higher levels of
7-(2-oxoethylguanine) in hepatic DNA of mice than
were obtained from ethyl carbamate. Furthermore,
for a given dose of ethyl or vinyl carbamate, the
levels of this adduct in hepatic DNA were -40-fold
higher than the levels of ethenoadenosine in the
hepatic RNA.
The preswent knowledge of the metabolism of ethyl
and vinyl carbamates in mouse liver is summarized
in Figure 5. It is a matter for further study whether
vinyl carbamate is a direct metabolite of ethyl
carbamate or whether each carbamate is
metabolized to a common reactive precursor of the
adducts found in the hepatic nucleic acids. As
shown in Figure 5, Scherer et al. (1981) have
hypothesized that the 7-(2-oxoethyl)guanine residue
in DNA may isomerize to yield a 06,7-(1'-
hydroxyethano)guanine adduct which might be
expected to be more mutagenic than the N-7
adduct. No evidence for this derivative has been
reported. However, Loeb and his colleagues
(Schaaper et al., 1982) have provided evidence for
the mutagenicity of depurinated sites in DNA
produced by carcinogenic electrophiles. This
consequence may follow the formation of 7-(2-
oxoethyl)guanine residues in DNA in vivo. In any
event, further work is necessary to establish the
importance of the 7-(2-oxoethyl)guanine adduct in
DNA to the carcinogenic processes induced by
ethyl and vinyl carbamate.
Safrole, estragole, and other alkenylbenzenes
About 30 naturally occurring alkenylbenzene
derivatives, usually relatively simple allyl- or
propenylbenzenes with methoxy and/or
methylenedioxy ring substituents, have been found
as components of many plants or their essential oils
(Miller & Miller, 1979; Miller et al., 1983). These
compounds occur in a variety of foods, but they are
especially prominent as active components of many
spices. Approximately 20 years ago safrole (1-allyl-
3,4-methylenedioxybenzene) was found to be
hepatocarcinogenic for rats and mice (IARC, 1976).
Three other hepatocarcinogens have since been
identified among this relatively new class of
naturally occurring carcinogens, e.g., estragole
(l-allyl-4-methoxybenzene), isosafrole (1-propenyl-
3,4-methylenedioxybenzene), and methyleugenol (1-
allyl-3,4-dimethoxybenzene) (Miller et al., 1983). In
addition, fl-asarone (cis-1-propenyl-2,4,5-tri-THE 1983 WALTER HUBERT LECTURE 7
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Figure 5 A possible pathway of metabolism of ethyl and vinyl carbamates in mouse liver in vivo which leads
to the formation of etheno adducts of adenosine and cytidine in RNA and a 7-(2-oxoethyl)guanine adduct in
DNA. The failure to detect vinyl carbamate as a metabolite of ethyl carbamate in vivo or in vitro (Dahl et al.,
1978, 1980) suggests that alternative pathways to these adducts may exist.
methoxybenzene) has induced mesenchymal
tumours of the small intestine in the rat (Miller et
al., 1983). Six related compounds did not show
carcinogenic activity in a recent study (Miller et al.,
1983); these were anethole (trans-1-propenyl-4-
methoxybenzene), eugenol (1-allyl-3-methoxy-4-
hydroxybenzene), elemicin (1-allyl-3,4,5-trimethoxy-
benzene), myristicin (1-allyl-3-methoxy-4,5-
methylenedioxybenzene), dill apiol (1-allyl-2,3-di-
methoxy-4,5-methylenedioxybenzene), and parsley
apiol (1-allyl-2,5-dimethoxy-3,4-methylenedioxy-
benzene). Of the derivatives shown to be
carcinogenic, isosafrole and f3-asarone occur only
rarely in plants, while safrole, estragole, and methyl-
eugenol occur more widely as plant constituents
(Leung, 1980). Although these compounds induce
high incidences of tumours under appropriate
conditions, they are orders of magnitude less active
than carcinogens such as the unsaturated pyr-
rolizidine alkaloids or aflatoxin B1. Because of this
fact and because they occur in the total food intake
of humans as components of foods or food
additives (spices) at no more than low parts 10'6
levels, the naturally occurring alkenylbenzenes
appear to make a relatively small contribution to
the burden of exogenous carcinogenic agents to
which humans are exposed.
Safrole is a major component of oil of sassafras
and a minor constituent of other essential oils, such
as the oils of sweet basil and cinnamon. Estragole
is a principal constituent of oil of tarragon and is
found in lesser amounts in oils of sweet basil and
anise and in other essential oils (Leung, 1980). The
carcinogenicity and metabolism of these two
carcinogens are very similar (Miller et al., 1982;
Miller et al., 1983). Both are complete
hepatocarcinogens on long-term feeding of relatively
high doses in adult mice. With small doses
administered only during the preweaning period
these compounds are initiators of
hepatocarcinogenesis in male mice. In this situation
some aspect of the normal adult male environment
apparently promotes the appearance approximately
one year later of gross liver tumours.8 J.A. MILLER & E.C. MILLER
In approaching the metabolic activation of these
carcinogens, note was taken of their allyl
substituents, the known metabolism of ethylbenzene
to 1'-hydroxyethylbenzene, and the data on the
metabolism of the carcinogenic pyrrolizidine
alkaloids ro form electrophilic allylic esters
(references in Miller & Miller, 1979). Studies with
rats and mice showed considerable metabolism of
safrole and estragole to urinary glucuronides of
their 1'-hydroxy metabolites (Borchert et al., 1973b;
Drinkwater et al., 1976). These 1'-hydroxy
metabolites were considerably more
hepatocarcinogenic than the parent alkenylbenzenes
(Borchert et al., 1973a; Drinkwater et al., 1976);
thus these metabolites were proximate carcinogens.
Evidence for the metabolism of the 1'-hydroxy
metabolites to reactive derivatives in vivo was
provided by the formation of covalently bound
adducts in liver DNA, RNA, and protein (Wislocki
et al., 1976; Phillips et al., 1981a,b).
H2C-CH =CH2
SAFROLE
OCH3
H2C-CH=CH2
ESTRAGOLE
The nucleophilic 1'-hydroxy metabolites, which
are not themselves reactive with tissue nucleophiles,
presented several possibilities for metabolism in vivo
to electrophilic products (Figure 6). One candidate
metabolite was a benzylic allylic ester. The synthetic
ester 1'-acetoxysafrole was electrophilic toward
nucleophiles such as guanosine and methionine
(Borchert et al., 1973b), but no evidence was found
for its formation by rat liver preparations from 1'-
hydroxysafrole and acetyl-coenzyme A (Wislocki et
al., 1976). However, 3'-phosphoadenosine-5'-
phosphosulfate-dependent binding of labelled 1'-
hydroxysafrole to RNA, presumably via a reactive
sulfuric acid ester, was demonstrated with liver
cytosols (Wislocki et al., 1976). A second proposed
route of activation was via metabolic epoxidation
of the allylic bond. Epoxidation of safrole and
estragole and of their 1'-hydroxy metabolites was
catalyzed by a cytochrome P-450-dependent system
in liver microsomes (Wislocki et al., 1976; Swanson
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Figure 6 Some possible pathways of metabolic activation in vivo of safrole and estragole to form
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et al., 1981), and, as expected, these epoxides were
electrophilic. 1'-Oxosafrole was also investigated,
since previous work (Oswald et al., 1971) suggested
its formation in vivo in the rat from safrole. This
derivative was electrophilic toward guanosine,
presumably through addition of the amino group of
this nucleophile to the allylic double bond
(Wislocki et al., 1976).
The mutagenicities of these electrophiles were
determined as another measure of their
electrophilicity in a biological situation. The 1'-
acetoxy and 2',3'-oxide derivatives of safrole,
estragole, and their 1'-hydroxy metabolites were
mutagenic for Salmonella typhimurium TA100, but
the 1'-oxo derivatives of safrole and estragole were
inactive (Wislocki et al., 1977; Swanson et al., 1979;
Phillips et al., 1981a). The carcinogenicities of many
of the known and possible electrophific- mwtabolites
of safrole and estragole have been determined in
rats and/or mice (Borchert et al., 1973a; Wislocki et
al., 1977; Miller et al., 1983). Although some of the
acetoxy and epoxy derivatives showed carcinogenic
activity, especially at sites of application, these
activities were generally lower than those of 1'-
hydroxysafrole and 1'-hydroxyestragole; possibly
little of these reactive compounds reached critical
sites in the cells. 1'-Oxosafrole showed no
carcinogenic activity in these tests.
In order to obtain more direct information on
the identities of the electrophilic metabolites that
might be of importance in carcinogenesis by
estragole, comparisons were made of the adducts
formed in vitro by reaction of deoxynucleosides
with electrophiles derived from I'-hydroxyestragole
and nucleoside adducts derived by enzymatic
hydrolyses of hepatic DNA from mice injected with
1'-[2',3'-3H]hydroxyestragole. The adducts formed
in vivo were cochromatographed by high
performance liquid chromatography with
nucleosides derived from the reaction of 1'-
acetoxyestragole, 1'-hydroxyestragole-2',3'-oxide, or
1'-oxoestragole with [14C]deoxyguanosine or
[14C]deoxyadenosine. The four nucleoside adducts
(I-IV) obtained from the hepatic DNA of mice
injected with the tritiated 1'-hydroxyestragole did
not comigrate with any major reaction products of
either 1'-hydroxyestragole-2',3'-oxide or 1'-
oxoestragole with deoxyguanosine or
deoxyadenosine. However, the in vivo adducts I-III
comigrated with 3 adducts from the reaction of 1'-
acetoxyestragole with deoxyguanosine and adduct
IV comigrated with the reaction product of the
acetoxy derivative with deoxyadenosine. On the
basis of these chromatographic data it was
concluded that the 4 principal adducts formed in
vivo in the hepatic DNA from 1'-hydroxyestragole
were products of the reaction of some
metabolically-formed ester of Y'-hydroxyestragole
with deoxyguanosine and deoxyadenosine residues
in the DNA. Large scale preparation of the 4
adducts permitted the characterization of their
structures (Phillips et al., 1981a) (Figure 7). Two of
the adducts (II and III) consist of 3'-isoestragole
residues bonded in the trans- or cis-configurations
to the 2-amino group of deoxyguanosine. A third
adduct (I) consists of a 1'-estragole residue attached
to the 2-amino group of deoxyguanosine. The
fourth adduct (IV) is comprised of a 3'-isoestragole
residue attached to the 6-amino group of
deoxyadenosine. Similar procedures were used to
demonstrate that the adducts formed in mouse liver
DNA in vivo from 1'-hydroxysafrole have structures
that are entirely analogous to those derived from
1'-hydroxyestragole (Phillips et al., 198lb).
These data suggest strongly that esters of 1'-
hydroxysafrole and 1'-hydroxyestragole are the
major electrophilic metabolites that react with the
hepatic DNA of mice treated with these two
carcinogens (Figure 8). As noted above Wislocki et
al. (1976) had obtained evidence for the formation
of a sulfuric acid ester of 1'-hydroxysafrole by a
3'-phosphoadenosine-5'-phosphosulfate-dependent
sulfotransferase activity in mouse and rat liver
cytosols. Recently, Eric Boberg in our laboratory
has investigated the role of this ester in
hepatocarcinogenesis by 1'-hydroxysafrole in the
mouse. Using an assay for the liver cytosolic
sulfotransferase activity toward 1'-hydroxysafrole
adapted from that of Wislocki et al. (1976), he
showed that hepatic sulfotransferase activity is
detectable on the day of birth of
C57BL/6 x C3H/He (B6C3F1) mice and that it
increases up to 3 weeks of age; thereafter the level
decreases and by day 60 the activity is in the same
range as on the day of birth. Pentachlorophenol,
which has been widely used as an inhibitor of
sulfotransferase activity (Meerman et al., 1980,
1981), inhibited the sulfotransferase activity for 1'-
hydroxysafrole in male and female mouse liver at a
10jumolar level. Likewise, as shown in Table III, the
administration of 0.05% of pentachlorophenol in the
diet of adult female CD-1 mice strongly inhibits the
formation of DNA, RNA, -and protein-bound
adducts formed after the injection of a single dose
of tritiated 1'-hydroxysafrole to 10-25% of those
in the liver of the control mice. Furthermore, when
1'-hydroxysafrole was fed in the diet of adult CD-1
mice, hepatic tumor formation was greatly inhibited
if the mice were fed simultaneously 0.05%
of pentachlorophenol (Table IV). Thus, penta-
chlorophenol inhibits the hepatic sulfo-
transferase that catalyzes the formation of the
sulfuric acid ester of l'-hydroxysafrole, reduces
dramatically the levels of DNA, RNA, and protein
adducts of this proximate carcinogen in the livers of
mice treated with this sulfotransferase inhibitor, and10 J.A. MILLER & E.C. MILLER
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Figure 7 Structures of the major DNA adducts formed in mouse liver in vivo from 1'-hydroxyestragole
(Phillips et al., 1981a).
also inhibits hepatic tumour formation by 1'-
hydroxysafrole. These data strongly implicate the
sulfuric acid ester as a critical metabolite in the
hepatic carcinogenicity of 1'-hydroxysafrole.
Table III The inhibition of the covalent binding of [2',3'-
3H]1'-hydroxysafrole to hepatic macromolecules of CD-1
adult female mice
The mice were fed the indicated diets for 4 weeks before
administration of a single 3-mg dose of [2',3'-3H]1'-
hydroxysafrole by stomach tube. They were killed 5h later
for isolation of the hepatic macromolecules.
Hepatic adducts
(pmolmg-' ofmacromolecule)
Diet DNA RNA Protein
Control 125+15a 420+95 365+90
0.05% Pentachlorophenol 20+10 45+25 100+ 5
aEach value is the average + the standard deviation for
3 pools of liver (2 livers per pool).
Table IV The inhibition by pentachlorophenol of the
induction of hepatomas in CD-1 adult female mice fed
1'-hydroxysafrole
Groups of 36 adult female CD-1 mice were fed diets
containing 1'-hydroxysafrole for 12 months. The
experiment was terminated at 16 months.
Dietary
J'-hydroxysafrole
(%)
Dietary Mice with
pentachloro- hepatomas
phenol (%) (%)a
Average
number of
hepatomas
per
mouse
0.27 0 81 1.6
0.27 0.05 17 0.2
0.14 0 50 1.1
0.14 0.05 6 0.06
0 0 0 0.0
0 0.05 7 0.07
aThe data are based on the number of mice that
survived for at least 12 months, when the first mice died
with gross tumours.THE 1983 WALTER HUBERT LECTURE 11
CH3
CH2-CH CH3
ESTRAGOLE
o --CH2 o __ CH2 CYTOSOLIC 0
\ CYT. P-450 SULFO-
0 NADPH, 02 0 TRANSFERASE
Q Q ~~~~~~~~PAPS
CH2-CH =CH2 CH-CH=CH2
SAFROLE OH
MAJOR ADDUCT
o-CH2
0 0
+CH-CH=CH2
--I--
-OS03
FROLE)
SAFROLE)
MINOR ADDUCTS
0o CH2 D-hydrolysis
0
oy NON-ENZYMATIC
+CH2-CH=CH2
O-C-CH3
I I
0
Figure 8 The proposed pathway of metabolic activation of safrole and estragole in mouse liver to form
DNA adducts.
Further evidence consistent with this conclusion
was obtained by the use of mice with the
brachymorphic trait. Sugahara and Schwartz (1979,
1982) found that brachymorphic mice, which are
characterized by an undersulfation of cartilage
glycosaminoglycans, have a low capacity for the
formation of 3'-phosphoadenosine-5'-phos-
phosulfate in the liver and some other tissues
as compared to normal mice. Dr. Alan Poland at
McArdle recognized that brachymorphic mice
might be useful tools in the analysis of the roles of
sulfate esters of certain carcinogens in the
carcinogenic processes that they induce since the
livers of these mice have a reduced capacity for the
formation of the sulfate ester of p-nitrophenol
(Lyman & Poland, 1983). Accordingly, in
collaboration with Dr. Poland we have bred
B6C3F2 mice from stock which carries the
brachymorphic trait. Among the littermates there
are -25% that are homozygous recessives for this
trait and are recognizable by their characteristic
short tails, short legs, and dome-shaped heads. The
phenotypically normal littermates include
heterozygous mice that contain both a normal and
a brachymorphic gene and homozygous mice that
contain 2 normal genes at the brachymorphic locus.
These two genotypes cannot be distinguished
phenotypically. As shown in Table V the livers of
12-day-old brachymorphic mice contain only -20%
as much of the DNA and RNA adducts of tritiated
Table V Hepatic adducts in 12-day-old male B6C3F2
mice treated with [2',3'-3H]1'-hydroxysafrole
The mice were injected intraperitoneally with a trioctanoin
solution of [2',3'-3H]1'-hydroxysafrole (0.20pmolgI body
wt) and were killed 9h later for isolation of the hepatic
macromolecules.
Phenotype
Hepatic adducts
(pmolmg-1 ofmacromolecule)
DNA RNA Protein
Normal 110+17a 200+34 210+33
Brachymorphicb 16+ 1 19+ 1 57+ 2
'Each analysis is the average + the standard deviation
for 3 pools of 5-6 livers each.
bThese mice are deficient in the hepatic synthesis of 3'-
phosphoadenosine 5'-phosphosulfate.
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1'-hydroxysafrole as did their phenotypically
normal littermates after the administration of this
proximate carcinogen. When similar mice were
initiated for hepatocarcinogenesis by the injection of
1'-hydroxysafrole only during the first 3 weeks of
life and then maintained without further treatment
for up to 15 months of age, the brachymorphic mice
had only -20% of the hepatic tumour incidence of
the phenotypically normal mice (Table VI). The
deficiency in hepatic 3'-phosphadenosine-5'-
phosphosulfate, reduced formation of hepatic
nucleic acid adducts of 1'-hydroxysafrole, and
reduced initiation of tumour formation in the liver
by this proximate carcinogen are strongly correlated
in these mice. Thus, all of the data in Tables III-VI
are consistent with the concept that the sulfuric acid
ester of 1'-hydroxysafrole is a major ultimate
carcinogenic metabolite of this proximate
carcinogen. Because of the close similarity of the
metabolism of estragole to that of safrole, we
presume that the sulfuric acid ester of 1'-
hydroxyestragole is similarly important in
hepatocarcinogenesis by estragole and its 1'-
hydroxy metabolite. However, we do not yet have
data confirming this presumption.
Table VI The incidences of hepatomas in normal
and brachymorphic male B6C3F2 mice treated with
1'-hydroxysafrole at 1-22 days of age
The mice were injected on Days 1, 8, 15, and 22 after birth
with trioctanoin solutions of 1'-hydroxysafrole; the relative
amounts injected on these days were in the ratio of
1:2:4:8. The experiment was terminated at 15 months.
F'-Hydroxy-
safrole
(umol/mouse) Phenotype
Mice with Average number
hepatomas ofhepatomas
(%) per mouse
3.7 Nornal 71a 2.2
3.7 Brachymorphicb 9 0.2
1.8 Normal 50 1.3
1.8 Brachymorphic 10 0.1
0 Normal 14 0.1
0 Brachymorphic 2 0.02
aThe data are based on the number of mice that
survived for at least 12 months, when the first mice died
with gross tumours.
bThese mice are deficient in the synthesis of 3'-phospho-
adenosine 5'-phosphosulfate.
While the genesis and nature of the major
adducts in hepatic DNA derived from safrole and
estragole are reasonably well defined, the important
problem remains of establishing the role of these
adducts in the initiation of carcinogenesis in the
mouse liver by these agents. Likewise, the possible
roles of the macromolecular adducts in the
promotion stage require further investigation.
Perspectives
As noted early in this lecture, it seems likely that
more carcinogenic agents exist in the living world
than are now known. A primary basis for this
statement is that, although only a relatively small
number of cellular components have been tested for
carcinogenic activity, over 30 of these diverse
structures have been found to be carcinogenic.
Man's food is derived almost entirely from living
systems and constitutes by far the major daily
source of non-nutritive chemicals, which may
include compounds that could increase
(carcinogens, initiators, promoters, cocarcinogens,
etc.) or decrease (anti-carcinogens, anti-mutagens,
etc.) the incidence of cancers in humans. The
primary evidence that diet may play a role in the
occurrence of major human cancers comes from
epidemiological studies on the incidences of cancers
among populations in different countries and
migrants between them, as well as investigations on
dietary differences between population groups
(Hirayama, 1979; Doll & Peto, 1981; National
Research Council, 1982). While some evidence
points to a causal role of certain naturally
occurring dietary agents (e.g., aflatoxins in hepatic
cancer) definitive evidence implicating dietary
components in the aetiologies of human cancers is
generally lacking. This situation probably reflects
the multi-factorial nature of carcinogenesis and
anti-carcinogenesis in man. Thus, in addition to the
strong associations of tobacco, alcoholic drinks,
and ultraviolet light with the genesis of specific
cancers, the probability of formation of cancers in
the last third of the life-span in a human being may
reflect in part long-term dietary intakes of agents
that increase cancer formation and/or of agents
that inhibit this process. Extensive experimental
studies have revealed a wide variety of mutagenic
agents (i.e., possible initiators of carcinogenesis) in
natural and over-heated foods (Sugimura et al.,
1982; Stich, 1982). Similarly, at least a dozen
naturally occurring substances of varied structure
appear to be anti-carcinogenic (Wattenberg, 1979).
Further innovative research is needed on these
interactions, especially in studies with human
beings.
Several naturally occurring components of living
systems are highly potent carcinogens in
experimental animals. These include aflatoxin B1,
cycasin, the unsaturated pyrrolizidine alkaloids, and
the as yet uncharacterized carcinogen(s) in bracken
fern (Miller & Miller, 1979). Ethyl carbamate and
the carcinogenic alkenylbenzenes have exhibited
moderate-to-weak carcinogenic activity in
experimental animals. The carcinogenic potentials
of none of the naturally occurring carcinogens from
living systems in human beings are known. SinceTHE 1983 WALTER HUBERT LECTURE 13
species and strain differences can play important
roles in the activities of chemical carcinogens
(Langenbach et al., 1983), it is possible that even
low life-time intakes of so-called "weak"
carcinogens could induce cancers in some humans
with especially predisposing genetic backgrounds
and dietary habits.
The molecular nature of carcinogenic processes
induced by chemical carcinogens is still unclear.
Extensive progress has been made on the
metabolism of chemical carcinogens to reactive
electrophiles in vivo and on the structural
characterization and properties of adducts of these
metabolites with DNA and other informational
macromolecules. However, these hypotheses have
generally lacked heuristic value for the prediction of
specific molecular mechanisms that could be tested.
Thus, research on chemical carcinogenesis has
reached an apparent impasse in attempts to extend
the data on the formation of specific DNA adducts
from electrophilic metabolites to the determination
of the molecular lesions directly responsible for the
initiation of carcinogenesis. Recent observations on
the occurrence in normal and tumour tissues from
experimental animals and humans of DNA
sequences homologous to portions of the
transforming genes of oncogenic retroviruses and
on the transforming activity of these sequences for
certain cell lines (Bishop, 1982; Rigby, 1982; Weiss,
1982; Weinberg, 1982; Newmark, 1983) have
provided new ideas on the possible nature of the
carcinogen-induced lesions that may be involved in
malignant transformation by chemicals. Exploration
of this phenomenon, as well as continuing analyses
of other effects of electrophilic reactions of the
macromolecules in relation to the carcinogen-
induced transformation, should bring us much
closer to a molecular understanding of malignant
transformation.
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Boberg and Drs. Peter Borchert, Gary A. Dahl, Norman
R. Drinkwater, Yaguan Li, David H. Phillips, Martin L.
Ribovich, Anne B. Swanson, and Peter G. Wislocki in
these studies during the past decade. The work in the
authors' laboratory was supported by Grants CA-07175,
CA-09135, CA-09020, and CA-22484 from the National
Cancer Institute, United States Public Health Service.
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